Skip to content
ClinCalc Pro
Menu
Inhaled corticosteroid (prodrug)

Ciclesonide

Brand names: Alvesco

Ciclesonide is an inhaled corticosteroid prodrug used for the regular preventive treatment of asthma.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It is activated by esterases in the airways to its active metabolite, which binds glucocorticoid receptors to reduce airway inflammation while limiting systemic and oropharyngeal exposure.

Prescribing in practice

  • It is a preventer for regular use and does not relieve acute bronchospasm, so a reliever inhaler remains necessary.
  • As with all inhaled corticosteroids, sustained high exposure can produce systemic corticosteroid effects.
  • Correct inhaler technique should be confirmed to ensure effective lung deposition.

Monitoring

Monitor asthma control, inhaler technique and, in children, growth during continued therapy.

Counselling the patient

  • Use every day as a preventer, even when symptom-free.
  • Keep a reliever inhaler for sudden breathlessness.
  • Local airway activation means mouth thrush is less common, but rinsing remains good practice.

Evidence & guidelines

Inhaled corticosteroids including ciclesonide are supported as maintenance asthma therapy in national asthma guidance.

Reference: SmPC Alvesco; BTS/SIGN Asthma 158 (2019); GINA 2024; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.